Cure8 research brief
IL-11 is implicated in fibrostenotic Crohn’s disease; determining whether it is a reversible therapeutic target could lead to treatments that prevent or reverse strictures rather than only managing inflammation or performing surgery.
Clinicians, researchers, drug developers, and patients concerned about Crohn’s-related strictures or anti-fibrotic therapies
This is a narrative review and abstract-level summary that weighs preclinical (mouse) and human tissue/serum evidence linking high stromal IL-11 to fibrosis and stricturing. Animal data are mixed: deleting Il11 can worsen acute epithelial injury yet reduce collagen deposition when deleted during chronic injury, suggesting context-dependent effects.
Early human-phase studies of a selective IL-11 inhibitor (LASN01) show systemic target engagement and tolerability outside IBD, but intestinal efficacy and stricture reversal remain untested.
The authors argue the decisive next step is trials that test selective IL-11 inhibition in patients with documented structural strictures, measure intestinal drug exposure, and include separate structural and inflammatory outcomes.
The article is a narrative review summarizing preclinical and preliminary human data; key trials testing selective IL-11 inhibitors in patients with documented intestinal strictures have not yet reported intestinal efficacy.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...
